A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study.
暂无分享,去创建一个
P. Kuna | M. Kupczyk | Michał Tarnowski | J. Jerzyńska | P. Majak | W. Machowiak | I. Poziomkowska-Gęsicka | R. Dobek | Beata Asankowicz-Bargiel | Eliza Barańska | Sławomir Garbicz | A. Latos | B. Majorek-Olechowska | A. Olech-Cudzik | Mirosława Rulewicz-Warniełło | A. Świderska | Przemysław Kopyto